Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers.
Erlotinib plus bevacizumab works in multiple cancer types when EGFR is amplified, demonstrating that molecular features matter more than tumor origin for treatment selection.
The KOSMOS I/II basket trial reports results of erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors identified by molecular profiling, spanning multiple cancer histologies. While erlotinib is EGFR-approved in NSCLC, this study extends the precision medicine rationale to biomarker-selected patients regardless of primary tumor origin.
What the study was
- Study design
- Basket trial (molecular profiling-guided therapy) — KOSMOS I and II studies
- Population
- Adults with EGFR-amplified metastatic solid tumors across multiple cancer types
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- International Journal of Clinical Oncology
Why it surfaced
Basket trial for EGFR-amplified tumors using erlotinib (established drug, low novelty) + bevacizumab. Precision oncology design is valid. Score 5/10: low novelty (these drugs are established, 1), moderate relevance (basket designs are informative, 2), basket trial design (2), general population (0).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.